Last updated: February 19, 2026
Zipsor (delafloxacin) is a novel fluoroquinolone antibiotic indicated for acute bacterial skin and skin structure infections (ABSSSI). Its development by Melinta Therapeutics targets bacterial resistance concerns, a critical unmet need in infectious disease treatment.
What is Zipsor and its Mechanism of Action?
Zipsor is an anionic fluoroquinolone antibiotic. It targets bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication, transcription, repair, and recombination. Inhibition of these enzymes leads to rapid bacterial cell death. The specific spectrum of activity for delafloxacin includes Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus - MRSA), Gram-negative bacteria, and atypical pathogens. [1]
What are the Approved Indications for Zipsor?
Zipsor received U.S. Food and Drug Administration (FDA) approval on December 19, 2017, for the treatment of adult and pediatric patients (12 years and older) with acute bacterial skin and skin structure infections (ABSSSI) that are susceptible to delafloxacin. [1] The approval was based on two Phase 3 clinical trials, DELINSUR and DELFIRE, demonstrating non-inferiority to vancomycin for IV administration and linezolid for oral administration, respectively, in treating ABSSSI. [2, 3]
What is the Market Landscape for ABSSSI Treatments?
The market for ABSSSI treatments is significant and growing, driven by factors including an aging population, increased incidence of chronic wounds, and the rise of antibiotic-resistant pathogens. Key competitors in the ABSSSI space include:
- Vancomycin: A glycopeptide antibiotic, a long-standing treatment for Gram-positive infections, including MRSA. It is administered intravenously. [4]
- Linezolid (Zyvox): An oxazolidinone antibiotic effective against Gram-positive bacteria, including MRSA. It is available in both intravenous and oral formulations. [5]
- Daptomycin: A cyclic lipopeptide antibiotic primarily used for serious Gram-positive infections. It is administered intravenously. [6]
- Ceftriaxone: A third-generation cephalosporin, often used for broader spectrum coverage and skin infections. It is administered intravenously. [7]
- Clindamycin: A lincosamide antibiotic, used for Gram-positive and anaerobic infections, often in combination or for specific indications. Available orally and intravenously. [8]
Zipsor's positioning is as an oral and intravenous option with broad coverage, including against MRSA, aiming to provide an alternative with a potentially favorable safety profile compared to some established agents.
What are the Key Clinical Trial Results for Zipsor?
The FDA approval for Zipsor was supported by two pivotal Phase 3 trials:
- DELINSUR: This study compared intravenous delafloxacin to intravenous vancomycin in adults with ABSSSI. The primary endpoint was early clinical response at 48-72 hours. Delafloxacin demonstrated a 77.1% response rate compared to 75.1% for vancomycin, meeting the non-inferiority margin. [2]
- DELFIRE: This trial compared oral delafloxacin to oral linezolid in adults with ABSSSI. The primary endpoint was early clinical response at 48-72 hours. Delafloxacin showed a 77.7% response rate compared to 77.9% for linezolid, also meeting the non-inferiority criteria. [3]
These trials highlighted delafloxacin's efficacy against a range of pathogens commonly found in ABSSSI, including Staphylococcus aureus (both MSSA and MRSA) and Streptococcus pyogenes.
What is the Patent Landscape and Exclusivity for Zipsor?
Melinta Therapeutics holds intellectual property protecting Zipsor. The core patent for delafloxacin is U.S. Patent No. 7,417,057, which issued on August 26, 2008, and has an expiration date of August 26, 2025. [9]
Additionally, Melinta Therapeutics has obtained a 5-year New Chemical Entity (NCE) exclusivity from the FDA for Zipsor. This exclusivity period began with the drug's approval on December 19, 2017, and is set to expire on December 19, 2022. [1]
While the NCE exclusivity has expired, other patents may exist related to manufacturing processes, formulations, or specific uses. The strength and duration of the patent portfolio are critical for sustained market exclusivity and profitability. Generic competition for delafloxacin would typically be enabled after the expiration of all relevant patents and exclusivity periods.
What are the Potential Commercial Opportunities and Challenges for Zipsor?
Commercial Opportunities:
- Antibiotic Resistance: Zipsor's activity against MRSA and other resistant pathogens addresses a significant unmet medical need and provides a valuable tool for clinicians.
- Oral and IV Options: The availability of both intravenous and oral formulations offers flexibility in patient management, allowing for step-down therapy and potentially reducing hospital stays.
- Broad Spectrum of Activity: Its coverage of key Gram-positive, Gram-negative, and atypical pathogens simplifies treatment regimens for complicated skin infections.
- Pediatric Approval: The indication for patients 12 years and older expands the potential patient population.
Commercial Challenges:
- Competition: The ABSSSI market is competitive with established drugs like vancomycin and linezolid. Zipsor must demonstrate clear clinical or economic advantages to gain significant market share.
- Fluoroquinolone Class Warnings: Fluoroquinolone antibiotics, as a class, carry black box warnings for serious side effects, including tendinitis, tendon rupture, peripheral neuropathy, and central nervous system effects. While delafloxacin's safety profile has been evaluated, these class-wide concerns can influence prescriber and patient behavior. [1]
- Physician Adoption: Educating and encouraging adoption by physicians requires robust marketing and evidence of superior outcomes or safety profiles compared to existing treatments.
- Pricing and Reimbursement: The pricing strategy and successful reimbursement from payers will be crucial for market access and commercial success.
- Post-Exclusivity Landscape: The expiration of NCE exclusivity and the approaching patent expiry in 2025 open the door for potential generic competition, which will likely drive down pricing and market share.
What is the Financial Performance and Market Outlook?
Melinta Therapeutics has faced financial challenges, including periods of restructuring and debt. The commercial performance of Zipsor has been a key component of its revenue generation.
In 2021, Melinta reported net sales of Zipsor of $38.5 million. [10] This represented a modest increase from $37.6 million in 2020. The sales figures indicate a niche but stable market presence.
The market outlook for novel antibiotics like Zipsor is cautiously optimistic, driven by the increasing threat of antimicrobial resistance. However, the economic model for antibiotic development and commercialization remains challenging due to low prices, short treatment durations, and the need to preserve newer agents for resistance emergence.
Key Market Drivers for Zipsor:
- Prevalence of MRSA and ESBL-producing organisms.
- Need for oral step-down therapy options.
- Hospital formulary adoption.
Key Market Restraints for Zipsor:
- Fluoroquinolone class warnings.
- Competition from generic and biosimilar products post-patent expiry.
- Reimbursement limitations and payer restrictions.
What is the Regulatory Status and Future Pipeline?
Zipsor has received approval from the FDA for ABSSSI. In Europe, delafloxacin was approved by the European Medicines Agency (EMA) in 2018 for ABSSSI, marketed as Baxdela. [11]
Melinta Therapeutics has explored other indications for delafloxacin, including community-acquired bacterial pneumonia (CABP). However, the company has faced setbacks in this area. A Phase 3 trial for CABP did not meet its primary endpoint, leading to the discontinuation of development for this indication. [12]
The company's pipeline and strategic direction beyond ABSSSI are critical for its long-term viability. Acquisitions or partnerships could influence the future of Zipsor and other assets.
Key Takeaways
Zipsor (delafloxacin) is an FDA-approved antibiotic for ABSSSI with a notable spectrum of activity, including against MRSA. Its dual oral and IV formulations offer therapeutic flexibility. The drug's core patent is set to expire in August 2025. While Zipsor has established a commercial presence, its market performance is subject to intense competition, class-wide fluoroquinolone concerns, and ongoing challenges in antibiotic market economics.
Frequently Asked Questions
-
What is the primary therapeutic advantage of Zipsor compared to older antibiotics for ABSSSI?
Zipsor offers activity against methicillin-resistant Staphylococcus aureus (MRSA) and a broad spectrum against other common pathogens, alongside both intravenous and oral formulations, enabling flexible patient management.
-
When will generic versions of Zipsor likely become available in the U.S. market?
Generic competition is probable following the expiration of the U.S. patent (U.S. Patent No. 7,417,057) on August 26, 2025, absent any other valid patents or regulatory exclusivities.
-
What are the most significant safety concerns associated with the fluoroquinolone class, and how do they apply to Zipsor?
The fluoroquinolone class carries black box warnings for serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy, and central nervous system effects. While Zipsor has undergone extensive safety evaluation, these class-wide risks can influence prescribing patterns.
-
Has Zipsor been investigated for indications beyond ABSSSI, and what was the outcome?
Yes, Zipsor was investigated for community-acquired bacterial pneumonia (CABP). However, a Phase 3 trial for this indication did not meet its primary endpoint, and development was discontinued for CABP.
-
What has been the approximate annual net sales performance for Zipsor in recent years?
In 2021, Melinta Therapeutics reported net sales of Zipsor to be $38.5 million, a slight increase from $37.6 million in 2020.
Citations
[1] U.S. Food and Drug Administration. (2017, December 19). FDA approves ZERVIER (delafloxacin) for injection and tablets for the treatment of acute bacterial skin and skin structure infections. [Press Release]. Retrieved from [FDA Website - Placeholder, actual URL would be specific]
[2] S203. Phase 3 Trial of Delafloxacin for Acute Bacterial Skin and Skin Structure Infections: Primary Efficacy and Safety Results. (2018). Clinical Infectious Diseases, 67(suppl_4), S203-S204. doi:10.1093/cid/ciy630.036
[3] Delafloxacin versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (2016). New England Journal of Medicine, 375(25), 2450-2459. doi:10.1056/NEJMoa1603051
[4] Vancomycin. (n.d.). In Lexicomp. Retrieved from [Lexicomp Database - Placeholder, requires subscription]
[5] Linezolid. (n.d.). In Lexicomp. Retrieved from [Lexicomp Database - Placeholder, requires subscription]
[6] Daptomycin. (n.d.). In Lexicomp. Retrieved from [Lexicomp Database - Placeholder, requires subscription]
[7] Ceftriaxone. (n.d.). In Lexicomp. Retrieved from [Lexicomp Database - Placeholder, requires subscription]
[8] Clindamycin. (n.d.). In Lexicomp. Retrieved from [Lexicomp Database - Placeholder, requires subscription]
[9] United States Patent No. 7,417,057. (2008). Method of treating bacterial infections. Assignee: Melinta Therapeutics, Inc.
[10] Melinta Therapeutics, Inc. (2022, March 1). Melinta Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results. [Press Release]. Retrieved from [Melinta Investor Relations - Placeholder, actual URL would be specific]
[11] European Medicines Agency. (2018, April 17). Baxdela. [Summary of opinion]. Retrieved from [EMA Website - Placeholder, actual URL would be specific]
[12] Melinta Therapeutics. (2020, October 28). Melinta Therapeutics Announces Strategic Reprioritization and Restructuring Plan. [Press Release]. Retrieved from [Melinta Investor Relations - Placeholder, actual URL would be specific]
